Nine Groups Adopt New Standardized Coding System

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 9 No 10
Volume 9
Issue 10

BETHESDA, Md-Nine organizations that fund cancer research have agreed to adopt a newly created standardized coding system, which is designed to make it easier to compare research papers and coordinate their scientific efforts. No common coding system existed previously.

BETHESDA, Md—Nine organizations that fund cancer research have agreed to adopt a newly created standardized coding system, which is designed to make it easier to compare research papers and coordinate their scientific efforts. No common coding system existed previously.

The Common Scientific Outline (CSO) was initially tested jointly by the National Cancer Institute (NCI) and the US Army Medical Research and Materiel Command (USAMRMC).

Seven other groups have now announced they will use the CSO as well. They are the American Cancer Society, Oncology Nursing Society, California Cancer Research Program, California Breast Cancer Research Program, Cancer Research Campaign of the United Kingdom, CaPCURE, and the Susan G. Komen Breast Cancer Foundation.

Other cancer research funding groups, nationally and internationally, are expected to adopt the CSO, which is organized around seven broad areas of interest to cancer scientists: biology; etiology; prevention; early detection, diagnosis, and prognosis; treatment; cancer control, survivorship, and outcomes research; and scientific model systems.

Better Coordination

“The CSO helps to lay a framework for better coordination among research organizations,” NCI director Richard D. Klausner, MD, said in a news release. “It puts everybody on the same page as they evaluate their scientific portfolios, helping to point to areas of possible collaboration and suggesting areas of duplicated or under supported study.”

The CSO, which underwent pilot testing jointly by the NCI and the USAMRMC, is designed for easy accessibility to physicians, researchers, and members of the general public. NCI is developing a database organized around the CSO system, which will provide users with a “straightforward way to access and explore institute-supported research by cancer type and scientific area,” the NCI said. The web-based information center is expected to be online by year’s end.

Recent Videos
Genetic consultation and next-generation sequencing can also complement treatment strategies for patients with pancreatic cancer.
Brett L. Ecker, MD, focused on the use of de-escalation therapy, which is gaining momentum in neuroendocrine tumors.
Immunotherapy options like CAR T-cell therapy and antigen-presenting cell-directed agents are currently being evaluated in the pancreatic cancer field.
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Pancreatic cancer is projected to become the second-leading cause of cancer-related deaths by 2030 in the United States.
2 experts are featured in this video
2 experts are featured in this video
2 experts are featured in this video
4 KOLs are featured in this series.
Related Content